## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.9% in mid entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (3.4%) confirms momentum alignment. Strong momentum (+3.8% 5-day acceleration). Outperforming sector by 4.4%. Caution: overbought RSI (71).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($589.72)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Unpleasant Surprises Could Be In Store For Thermo Fisher Scientific Inc.'s (NYSE:TMO) Shares**
- Source: Simply Wall Street | 20260105T191647 | Somewhat-Bearish | Relevance: 100%
- Thermo Fisher Scientific Inc. (NYSE:TMO) has a high price-to-earnings (P/E) ratio of 33.9x, which is significantly above the market average of 19x. While the company's recent earnings growth of 8.2% was positive, its three-year EPS has seen a 2.4% decline, and future growth estimates are only comparable to the market. This suggests that investors might be overlooking the company's average growth expectations and paying a premium for the stock, potentially setting themselves up for disappointment if the P/E ratio adjusts to align with growth prospects.

**2. Thermo Fisher (TMO) stock rises 2% to start 2026 as earnings, key data loom**
- Source: ts2.tech | 20260103T200305 | Somewhat-Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. (NYSE: TMO) shares rose 2.25% to $592.51 on Friday, outpacing the S&P 500, as investors anticipate late-January earnings and key U.S. economic data. The company is nearing its 52-week high, with financial strategists cautioning about rich equity valuations. Investors will closely watch management's 2026 outlook and updates on order trends, especially regarding its planned acquisition of Clario Holdings.

**3. Synergy Asset Management LLC Has $3.41 Million Position in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20260103T141524 | Bullish | Relevance: 100%
- Synergy Asset Management LLC significantly increased its stake in Thermo Fisher Scientific Inc. by 100%, now holding 7,030 shares valued at $3.41 million. The company reported strong Q3 earnings, beating estimates, and announced a new $5.0 billion share repurchase program and a quarterly dividend of $0.43. Despite institutional confidence, company insiders have recently sold a substantial amount of stock.

**4. Thermo Fisher Scientific stock reaches 52-week high at $610.97 By Investing.com**
- Source: Investing.com UK | 20260105T205549 | Bullish | Relevance: 100%
- Thermo Fisher Scientific (TMO) stock has reached a 52-week high of $610.97, reflecting strong performance with a 1-year change of 13.48% and a six-month price return of 38.24%. Despite its impressive growth, InvestingPro data suggests the stock may be overvalued. The company has also seen positive analyst ratings and is expanding its bioprocessing capabilities in Asia.

**5. Thermo Fisher Scientific stock jumps as Evercore lifts target, with earnings in focus**
- Source: ts2.tech | 20260105T202149 | Bullish | Relevance: 100%
- Thermo Fisher Scientific Inc. shares rose about 2.4% after Evercore ISI raised its price target to $650 from $610, maintaining an "outperform" rating. The stock's performance places it in focus ahead of its late-January earnings report, where investors will seek insights into drugmaker and laboratory spending trends. The company's upcoming results will also provide updates on its China market exposure, its acquisition of Clario, and overall demand trends for lab tools and services.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 24.8x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +10%, $685 target (+12%)). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $229.6B |
| Beta | 0.91 |
| 52W Range | $385.46 - $611.38 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 24.8 |
| Current P/E | 26.9 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.1% to 4.9% (+3.8% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 3.4% confirms short-term momentum alignment. Outperforming sector by 4.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.83), confirming momentum. RSI overbought at 71, risk of mean reversion. OFD pattern: +FTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.90% (CS: 88) | Strong |
| RSI_14 | 70.8 | Overbought |
| MACD Histogram | 2.83 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 1.062x | Above |
| vs SMA200 | 1.258x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $611.34
- **Stop Loss:** $589.72 (3.5% risk)
- **Target:** $643.77 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $23,842.26
- **Portfolio %:** 23.84%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*